NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Caledonia Mining Corporation Plc ("Caledonia Mining" or the "Company") (NYSE: CMCL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Caledonia Mining and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the cla ...

Core Viewpoint - A class action lawsuit has been filed against Blue Owl Capital Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [1][2]. Financial Performance - Blue Owl reported fee-related earnings of $376.2 million for Q3 2025, missing consensus estimates, with fee-related earnings margins at 57.1%, falling short by approximately 20 basis points [3]. - Performance revenue declined by 33% year-over-year, amounting to only $188,000 [3]. Stock Price Movements - Following the Q3 earnings report, Blue Owl's stock price dropped by $0.70, or 4.23%, closing at $15.86 on October 30, 2025 [4]. - After the announcement of a merger agreement between Blue Owl Capital Corporation and Blue Owl Capital Corporation II, the stock price fell by $0.74, or 4.72%, to close at $14.95 on November 6, 2025 [4]. - A subsequent article from The Financial Times indicated potential losses for investors in connection with the merger, leading to a further decline in stock price by $0.85, or 5.8%, closing at $13.77 on November 17, 2025 [5]. - On November 19, 2025, Blue Owl announced the termination of the proposed merger due to current market conditions [6].

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Bancorp, Inc. ("Bancorp" or the "Company") (NASDAQ: TBBK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Bancorp and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On October 30, 2025, ...

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride admitted to issues with customer experience, resulting in an estimated 10,000-15,000 fewer enrollments, causing the stock to plummet by $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/ ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04, or more than 32%, from $129.95 to $87.91 per share [8].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Arizona, captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 12, 2026, to request to be appointed to lead the case [3]. Group 2: Company Operations and Safety Claims - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Indonesia through its affiliate PT Freeport Indonesia, where the Indonesian government holds a commercial interest [4]. - The company has been accused of overstating its commitment to safety, as unsafe mining practices at the Grasberg mine were likely to result in worker fatalities [5]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide that trapped seven team members [6]. - Following an update on September 24, 2025, indicating two fatalities and a projected 4% decrease in copper sales and 6% decrease in gold sales, the stock fell by $7.69 per share (almost 17%) [7]. - On September 25, 2025, reports of strained relations with the Indonesian government led to a further decline of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, suggested that the landslide was preventable, further impacting investor confidence [9].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Integer Holdings Corporation and certain executives, alleging misleading statements and failure to disclose adverse facts about the company's business and operations during the class period from July 25, 2024, to October 22, 2025 [1] Company Overview - Integer Holdings Corporation, based in Plano, Texas, is one of the largest medical device contract development and manufacturing organizations globally, focusing on cardiac rhythm management and cardiovascular medical devices [2] - Approximately 60% of Integer's total revenue is generated from its cardiovascular product line, which includes electrophysiology devices that diagnose and map the heart's electrical activity [2] Industry Context - Prior to the class period, the electrophysiology device market experienced a technological revolution with the development of pulse field ablation procedures, which treat atrial fibrillation [3] - The integration of electrophysiology devices and pulse field ablation platforms became a significant growth driver for Integer's cardiovascular segment [3] Allegations in the Class Action - The lawsuit claims that during the class period, Integer's executives made materially false and misleading statements regarding the company's competitive position and sales performance in the electrophysiology market [4] - Specific allegations include: 1. Integer overstated its competitive position in the EP manufacturing market 2. The company experienced a deterioration in sales for two of its EP devices, contrary to claims of strong customer demand 3. Integer mischaracterized its EP devices as a long-term growth driver for its cardiovascular segment [4] Disclosure of Financial Performance - On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, which was below analysts' expectations [5] - The company projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, with expectations of declining sales for three new products, including two electrophysiology products [5] - Following this disclosure, Integer's stock price fell by $35.22, or over 32%, from $109.11 to $73.89 per share [5]

Core Viewpoint - Venu Holding Corporation is under investigation for potential violations of federal securities laws and unlawful business practices by its senior management [1]. Group 1: Company Overview - Venu conducted its initial public offering on November 27, 2024, offering 1.2 million shares at a price of $10.00 per share [3]. - The company reported third-quarter financial results on November 14, 2025, with revenue of $5.38 million, which is a 1.3% decline year-over-year and $2.05 million below consensus estimates [3]. Group 2: Market Reaction - Following the financial results announcement, Venu's share price dropped by $2.37, or approximately 21.45%, from $11.05 on November 14, 2025, to close at $8.68 on November 17, 2025 [3].

Core Viewpoint - A securities class action lawsuit has been filed against CarMax, Inc. for allegedly making false and misleading statements regarding its growth prospects during the Class Period from June 20, 2025, to November 5, 2025 [1][2]. Summary by Sections Allegations Against CarMax - The complaint claims that CarMax's management overstated the company's growth potential, attributing earlier growth in the 2026 fiscal year to temporary factors related to customer behavior influenced by tariff speculation [2]. - It is alleged that the positive statements made by the defendants about CarMax's business operations and future prospects were materially misleading and lacked a reasonable basis [2]. Lead Plaintiff Process - Investors in CarMax have until January 2, 2026, to apply to be appointed as lead plaintiff representatives in the class action lawsuit [3]. - The lead plaintiff will represent the interests of all class members and will select legal counsel to direct the litigation [3]. Law Firm Background - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and has a history of significant recoveries in securities litigation [4]. - The firm represents both individual and institutional investors and has received numerous accolades for its work in the field [4].